An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency
Latest Information Update: 11 May 2022
Price :
$35 *
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 06 Jul 2017 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 22 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 06 Mar 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.